Equity Capital Raises and Major M&A Deals. Biotechnology companies have not had any trouble raising capital, in either public or private markets, to fund their research. Total capital raised by initial public (IPO) and follow-on (FO) offerings in the three quarters of 2019 exceeded the full year 2018 number ($555mm vs. $526mm, respectively, +5%). The sector also experienced megamergers between pharmaceutical giants:  Bristol-Myers Squibb (BMY)  acquired Celgene for $74 billion, Takeda Pharmaceutical (TAK) bought Shire for $62 billion, and AbbVie (ABBV) is set to acquire Allergan (AGN) for $63 billion. 

Smallcap Biotechs Have Been at the Forefront of the Majority of Medical Breakthroughs. Smallcap biotechnology companies are responsible for most of the major breakthroughs in the sector. As biotech stocks were reaching their peak in the middle of this decade, innovative drugs reached the market to fight common, serious diseases such as lung cancer and hepatitis C. Recently, companies are more focus on rare indications.

There Is No Shortage of Investment Opportunities in the Sector. Wall Street’s biggest bulls expect 159 of the 218 stocks in the Nasdaq Biotech Index to double over the next year based on data compiled by Bloomberg. Wall Street analysts see potential for companies in the index to trade at prices ten times higher than their current values in 12 months.

Equity Capital Raises and Major M&A Deals. Biotechnology companies have not had any trouble raising capital, in either public or private markets, to fund their research. Total capital raised by initial public (IPO) and follow-on (FO) offerings in the three quarters of 2019 exceeded the full year 2018 number ($555mm vs. $526mm, respectively, +5%). The sector also experienced megamergers between pharmaceutical giants:  Bristol-Myers Squibb (BMY)  acquired Celgene for $74 billion, Takeda Pharmaceutical (TAK) bought Shire for $62 billion, and AbbVie (ABBV) is set to acquire Allergan (AGN) for $63 billion. 

Smallcap Biotechs Have Been at the Forefront of the Majority of Medical Breakthroughs. Smallcap biotechnology companies are responsible for most of the major breakthroughs in the sector. As biotech stocks were reaching their peak in the middle of this decade, innovative drugs reached the market to fight common, serious diseases such as lung cancer and hepatitis C. Recently, companies are more focus on rare indications.

There Is No Shortage of Investment Opportunities in the Sector. Wall Street’s biggest bulls expect 159 of the 218 stocks in the Nasdaq Biotech Index to double over the next year based on data compiled by Bloomberg. Wall Street analysts see potential for companies in the index to trade at prices ten times higher than their current values in 12 months.

Drug Approvals Slowed Down. Iqvia found that success rates of clinical trials in all stages fell to 11.4% last year, representing a number below the 10-year average of 14%. Despite remaining strong in a historical sense, regulatory approvals have also slowed down. Thus far, the US Food and Drug Administration (FDA) has approved 27 drugs in YTD-2019 compared to a record 59 approvals in 2018. 

Focus on Rare Diseases. Biotechnology companies have recently focused on treatments of rarer diseases, such as spinal muscular atrophy or a form of hereditary blindness. There is no question these drugs are of high value for patients and individual companies. However, they generally don’t reach enough patients to boost the entire sector’s fortunes. Meanwhile, clinical trials in large potential markets for treatments of Alzheimer’s disease or certain liver conditions continue to disappoint.

The Number of Potential Buyers is Shrinking. Large pharmaceutical companies, which have strong cash flow and investment-grade balance sheets, tend to buy a larger peer to achieve revenue growth. As the sector has undergone megamergers, the pool of potential buyers appears to be shrinking. In addition, some of the M&A transactions recently announced continue to hit obstacles delaying their closings. For example, the acquisition by Roche’s (RHHBY) of Spark Therapeutics for $4.8 billion was announced in February. It has not closed due to an extended antitrust review by regulators.

Drug Approvals Slowed Down. Iqvia found that success rates of clinical trials in all stages fell to 11.4% last year, representing a number below the 10-year average of 14%. Despite remaining strong in a historical sense, regulatory approvals have also slowed down. Thus far, the US Food and Drug Administration (FDA) has approved 27 drugs in YTD-2019 compared to a record 59 approvals in 2018. 

Focus on Rare Diseases. Biotechnology companies have recently focused on treatments of rarer diseases, such as spinal muscular atrophy or a form of hereditary blindness. There is no question these drugs are of high value for patients and individual companies. However, they generally don’t reach enough patients to boost the entire sector’s fortunes. Meanwhile, clinical trials in large potential markets for treatments of Alzheimer’s disease or certain liver conditions continue to disappoint.

The Number of Potential Buyers is Shrinking. Large pharmaceutical companies, which have strong cash flow and investment-grade balance sheets, tend to buy a larger peer to achieve revenue growth. As the sector has undergone megamergers, the pool of potential buyers appears to be shrinking. In addition, some of the M&A transactions recently announced continue to hit obstacles delaying their closings. For example, the acquisition by Roche’s (RHHBY) of Spark Therapeutics for $4.8 billion was announced in February. It has not closed due to an extended antitrust review by regulators.

The prevailing view in the capital markets is that the biotechnology sector represents a great opportunity for growth investors willing to understand the risks inherent to the sector. The biotechnology industry is a highly specialized area with no shortage of innovative technologies and investment opportunities. As large pharmaceutical companies persist under pressure by drug pricing, small biotechnology companies continue to develop medical breakthroughs for the benefit of patients. Microcap biotechnology companies with strong development pipelines and differentiating assets have the potential to grow faster than already established companies and emerge as industry leaders.

Sources:

1. Bloomberg Business Intelligence Biotechnology
2. Capital IQ
3. Wall Street Journal

The prevailing view in the capital markets is that the biotechnology sector represents a great opportunity for growth investors willing to understand the risks inherent to the sector. The biotechnology industry is a highly specialized area with no shortage of innovative technologies and investment opportunities. As large pharmaceutical companies persist under pressure by drug pricing, small biotechnology companies continue to develop medical breakthroughs for the benefit of patients. Microcap biotechnology companies with strong development pipelines and differentiating assets have the potential to grow faster than already established companies and emerge as industry leaders.

Sources:

1. Bloomberg Business Intelligence Biotechnology
2. Capital IQ
3. Wall Street Journal